Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06162377
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Methylnaltrexone — DRUG
    Given by SC (injection)

Study Details

To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.

Key Dates

Start date
Jan 10, 2024
Status verified
Jun 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Methylnaltrexone
    Participants will be given 14 pre-filled syringes of methylnaltrexone. Participants will be instructed how to take the drug as an injection under the skin of your abdominal area.

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Juan Cata, MD
[email protected]
713-792-7452
Juan Cata, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies